Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
Cidara Therapeutics (Nasdaq: CDTX) announced that its CEO, Jeffrey Stein, Ph.D., will participate in two upcoming virtual conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cidara Therapeutics (Nasdaq: CDTX) announced that its CEO, Jeffrey Stein, Ph.D., will participate in two upcoming virtual conferences. The first is the Stifel 2020 Virtual Healthcare Conference, scheduled for November 17, 2020, at 2:00 PM ET. The second event is the 3rd Annual Evercore ISI HealthCONx Conference on December 2, 2020, at 11:20 AM ET, featuring a panel discussion focused on fungal needs. Cidara specializes in developing long-acting therapeutics for fungal and viral infections, including its lead antifungal candidate, rezafungin.
Details
News Market Reaction – CDTX
The recorded move for CDTX in the trading session of this news was +23.53%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences: the Stifel 2020 Virtual Healthcare Conference and 3rd Annual Evercore ISI HealthCONx Conference.
Stifel 2020 Virtual Health Conference
| Date: | Tuesday, November 17, 2020 |
| Time: | 2:00 PM Eastern Time |
| Format: | Presentation |
A live audio webcast of the presentation will be available in the Investors section on the Company’s website at www.cidara.com.
3rd Annual Evercore ISI HealthCONx Conference
| Date: | Wednesday, December 2, 2020 |
| Time: | 11:20 AM Eastern Time |
| Format: | Panel Discussion - No Fungus Among Us: Addressing an Important Fungal Need |
About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Karen O’Shea, Ph.D.
LifeSci Communications
(929) 469-3860
koshea@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.